Arcadia Biosciences, Inc. (RKDA) Stock Price & Analysis
Arcadia Biosciences, Inc. (RKDA) — MoonshotScore 17/100 (Weak band), calculated Oct 11, 2026. Price $0.2643 (-3.40%), as of the Oct 9, 2026 trading session.
Educational signal · not a buy or sell recommendation · How to read this
Arcadia Biosciences, Inc. · RKDA
Arcadia Biosciences, Inc. focuses on developing and marketing plant-based health and wellness products. The company aims to improve crop performance and value through genetic advancements, primarily in wheat.
Price as of Oct 9, 2026
Key Statistics
MoonshotScore v2 · Arcadia Biosciences (RKDA)
WeakWhy this rating? Method, drivers & history
Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.
- Business Quality — Is this a genuinely good business?
- Financial Safety — Could this blow up on me?
- Valuation — Am I paying a fair price?
- Growth Durability — Is the growth real and likely to last?
- Momentum — Is the market already moving on this?
Bottom-tier quality and weak growth, though the balance sheet is only middling, and the price trend has turned against it. Business Quality: Poor; Financial Safety: Okay; Valuation: Fair; Growth Durability: Fading; Momentum: Falling.
- quarterly revenue $1M (Q2 FY2026, quarter ended Jun 30, 2026)
- EPS beat 3 of 8
Holding back: weak fundamentals, soft growth, weak price trend
What has the MoonshotScore done over time?
| Recorded | Score | Band |
|---|---|---|
| 17 | Weak | |
| 17 | Weak | |
| 17 | Weak | |
| 17 | Weak | |
| 17 | Weak | |
| 17 | Weak |
The score was 17 in the stored Oct 9, 2026 snapshot and remains 17 in the current publication computed Oct 11, 2026 (0); the largest pillar moves were Growth Durability -3 and Valuation -1; the pillar moves offset under the sector-relative weighting, so the headline score is unchanged. This current publication is not yet represented in the immutable snapshot archive.
Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.
Computed · Educational signal · not a buy or sell recommendation · How the MoonshotScore is computed →
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $0.2643 | |
| Change on the day | -3.40% | |
| 52-week range | $0.222 – $6.71 | |
| Shares traded on the day | 385.8K |
Price & events
Watch the RKDA film — every key number, told as a short cinematic story
~2 min · open the film
What is Arcadia Biosciences (RKDA), and what does it report?
Short answer · as of
A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. Arcadia Biosciences, Inc. (RKDA) is the company analyzed here. It employs 8 people and is led by Thomas J. Schaefer. In Q2 FY2026 it reported revenue of $1M and net income of -$6M.
What do the latest results show for Arcadia Biosciences (RKDA)?
Short answer · as of
The most recent reported quarter, Q2 FY2026, carried revenue of $1M. Against analyst estimates the company has EPS beat 3 of 8 reports.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q2 FY2026 | $1M | -$6M | -$4.58 (diluted) |
| Q1 FY2026 | $1M | -$4M | -$3.21 (diluted) |
| Q4 FY2025 | $901,000 | -$1M | -$0.98 (diluted) |
| Q3 FY2025 | $1M | $856,000 | $0.62 (diluted) |
What are the financial strengths and risks for Arcadia Biosciences (RKDA)?
Short answer
What is holding it back is weak fundamentals, soft growth, weak price trend. The distress and quality screens read Piotroski F 3. Trailing ratios: current ratio 3.49.
Data-derived red flags
- Inconsistent delivery — missed Wall Street EPS estimates in 5 of the last 8 reported quarters.
- Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
How does Arcadia Biosciences compare with its peers?
Short answer
Arcadia Biosciences's score ranks 13th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.
| Company | Price | Market value | Score |
|---|---|---|---|
| $111.54 Oct 9, 2026 | $17.1B | 98 5-pillar Oct 11, 2026 | |
| $124.75 Oct 9, 2026 | $1.32B | 92 5-pillar Oct 11, 2026 | |
| $32.51 Oct 9, 2026 | $437M | 85 5-pillar Oct 11, 2026 | |
| $67.48 Oct 9, 2026 | $32.4B | 74 5-pillar Oct 11, 2026 | |
| $5.02 Oct 9, 2026 | $6.48B | 63 5-pillar Oct 11, 2026 | |
| $13.22 Oct 9, 2026 | $8.85B | 62 5-pillar Oct 11, 2026 | |
| $49.86 Oct 9, 2026 | $2.90B | 55 5-pillar Oct 11, 2026 | |
| $15.04 Oct 9, 2026 | $2.71B | 44 5-pillar Oct 11, 2026 | |
| $11.11 Oct 9, 2026 | $1.50B | 40 5-pillar Oct 11, 2026 | |
| $0.33 Oct 9, 2026 | $20.8M | 38 5-pillar Oct 11, 2026 | |
| $8.35 Oct 9, 2026 | $1.05B | 38 5-pillar Oct 11, 2026 | |
| $1.60 Oct 9, 2026 | $45.8M | 36 5-pillar Oct 11, 2026 | |
| Arcadia Biosciences (RKDA) — this page | $0.2643 | — | 17 |
Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Insider activity
Form 4 records via FMP · Of the newest 100 records, those within the last 180 days, newest dated Sep 10, 2026
- Transactions
- 4
- Identified insiders
- 4
- Purchases
- 0
- Sales
- 0
- Other transactions
- 4
Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
Investor Questions: RKDA Stock
These answers are editorial: 1 of these 9 answers is drawn from the RKDA research dossier (written Mar 17, 2026 by gemini-2.0-flash); the other 8 are question templates that restate figures shown above. Figures in this section are not part of the source register.
What does the MoonshotScore mean for RKDA?
RKDA carries the MoonshotScore stated above — the Weak band. This is an educational research signal, not a buy or sell recommendation. The number comes from the five-pillar engine (business quality, financial safety, valuation, growth durability, momentum), re-ranked daily against sector peers. Arcadia Biosciences, Inc. focuses on developing and marketing plant-based health and wellness products.
Is RKDA a good stock to buy?
Stock Expert AI does not rate RKDA buy, sell or hold. Arcadia Biosciences, Inc. carries a MoonshotScore, in the Weak band, a research rating against its peers rather than a forecast. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.
What is the RKDA stock price today?
The last price recorded on this page for Arcadia Biosciences, Inc. (RKDA) is $0.2643, as of the Oct 9, 2026 trading session (source: Financial Modeling Prep (FMP) · quote). It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What does Arcadia Biosciences, Inc. do?
Arcadia Biosciences, Inc. is an agricultural biotechnology company focused on developing and marketing plant-based health and wellness products. The company specializes in crop improvement, particularly in wheat, to enhance farm economics by improving crop performance in the field. Arcadia's efforts aim to increase the value of crops as food ingredients, health and wellness products, and for industrial applications.
What are the key factors to evaluate for RKDA?
Arcadia Biosciences, Inc. (RKDA) holds a MoonshotScore in the low range. This could include grants, tax credits, or other forms of financial assistance. Not financial advice.
How frequently does RKDA data refresh on this page?
RKDA's price is the last quote we recorded, from the Oct 9, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.
What has driven RKDA's recent stock price performance?
Arcadia Biosciences, Inc. (RKDA) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Proprietary crop technologies. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider RKDA overvalued or undervalued right now?
Arcadia Biosciences, Inc. (RKDA) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research RKDA before investing?
Before investing in Arcadia Biosciences, Inc. (RKDA), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 17, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources — records for every figure on this page (16 figures)
The 16 rows below are exactly the facts the evidence-backed sections of this page printed — the 10-second verdict, the MoonshotScore, price and market value, the five questions with their receipts, and the records behind this page. Known dates and sources are recorded on their own rows; an em dash or UNRECORDED tier preserves a stored observation without inventing either. The quarterly income statement is provider-standardized (FMP) under one row, and scale definitions — a 0-100 rating, the band ladder, the Piotroski 0–9 range — are fixed rather than measured. No number in those sections was generated by a model. The register does not cover quoted third-party headlines, the dated council readings, or the Frequently Asked Questions; each of those says where it came from where it stands.
"As of" is the date the value is true for where the source carries one — a quarter end, a filing date, a price close, the day the score was computed. A cached observation with no source date remains undated; the page publication date is not used as a substitute.
FMP — 8 facts from Financial Modeling Prep endpoint families
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
px.last | Latest provided price | $0.2643 | FMP | Financial Modeling Prep (FMP) · quote — Dated to the US trading session the price belongs to, derived from the quote record's timestamp (weekend and pre-open reads roll back to the previous weekday; exchange holidays are not modelled). The record does not establish an exchange execution time. Retrieved 2026-10-10T22:14:50.219Z. | |
px.change | Change on the day | -3.40% | FMP | Financial Modeling Prep (FMP) · quote | |
px.change_abs | Change on the day, in dollars | −$0.0093 | FMP | Financial Modeling Prep (FMP) · quote | |
fin.q_revenue | Revenue, Q2 FY2026 | $1M | FMP | Financial Modeling Prep (FMP) · income statement (quarterly) | |
px.volume | Shares traded on the day | 385.8K | FMP | Financial Modeling Prep (FMP) · quote | |
fin.q_income | Net income, Q2 FY2026 | -$6M | FMP | Financial Modeling Prep (FMP) · income statement (quarterly) | |
fin.q_table | Quarterly income statement | 4 quarters through Q2 FY2026 | FMP | Financial Modeling Prep (FMP) · income statement (quarterly), as filed | |
own.insiders | Insider transactions via FMP | 4 transactions · 0 purchases, 0 sales, 4 other transactions · 4 identified insiders · of the newest 100 records, those within the last 180 days, newest dated Sep 10, 2026 | FMP | Financial Modeling Prep (FMP), carrying Form 4 transaction records — Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent. |
UNRECORDED — 6 facts from stored observations whose source was not recorded
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
earn.history | Reported versus estimated, recent quarters | EPS beat 3 of 8 | UNRECORDED | Stored earnings-history observation — Captured 2026-08-21 · Expired observation | |
px.range52 | 52-week range | $0.222 – $6.71 | UNRECORDED | Stored company-profile observation — Captured 2026-10-07 | |
id.employees | Employees | 8 | UNRECORDED | Stored company-profile observation — Captured 2026-10-07 | |
id.ceo | Chief executive | Thomas J. Schaefer | UNRECORDED | Stored company-profile observation — Captured 2026-10-07 | |
fin.scores | Distress and quality screens | Piotroski F 3 | UNRECORDED | Stored financial-scores observation — Captured 2026-10-10 · Expired observation | |
fin.ratios | Return and yield ratios (trailing twelve months) | current ratio 3.49 | — | UNRECORDED | Stored key metrics — Date unknown |
OURS — 2 facts from Stock Expert AI's own score and rank
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
ours.moonshot | MoonshotScore v2 | 17 of 100 · Weak · pillars 6 / 42 / 62 / 25 / 3 | OURS | Stock Expert AI MoonshotScore v2 engine | |
ours.moonshot_change | MoonshotScore movement | 17 (stored snapshot Oct 9, 2026) → 17 (current publication computed Oct 11, 2026) (0) | OURS | Stock Expert AI current score publication and immutable score snapshots — The current score publication is not yet represented in the immutable snapshot archive. |
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com
Data provided for informational purposes only.